BCAL Diagnostics Limited (BDX.AX)
| Previous close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.1000 x N/A |
| Ask | 0.1050 x N/A |
| Day's range | 0.1000 - 0.1000 |
| 52-week range | 0.0510 - 0.2100 |
| Volume | |
| Avg. volume | 192,909 |
| Market cap | 25.164M |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireBCAL Findings Presented at 2023 ASCO Annual Meeting
BCAL Diagnostics Limited (ASX:BDX) (BCAL or Company) today announced the presentation of data demonstrating the potential for detection of early breast cancer using a plasma lipidomic biomarker signature. BCAL is developing a non-invasive blood screening test that is intended to be used alongside breast cancer screening methods, such as mammography. The poster, "Lipidomic Signature From Plasma to Detect Localised Breast Cancer," was presented at the 2023 ASCO Annual Meeting (Chicago, 2-6 June 20
- PR Newswire
BCAL DIAGNOSTICS OPENS NEW LABORATORY IN SYDNEY AS IT ACCELERATES DEVELOPMENT OF ITS BREAST CANCER BLOOD SCREENING TOOL
BCAL Diagnostics Limited (ASX:BDX) (BCAL or Company) an Australian-based biotechnology company announced the opening of its development and clinical service laboratory in Sydney. This step marks an important milestone for the company as it advances commercialization of its non-invasive blood screening that is initially intended to be used alongside other breast cancer screening methods, with results to date demonstrating 91% sensitivity and 80% specificity. The technology will initially compleme
